Lantheus to Present New Florbetaben F18 Data at CTAD 2025
Lantheus Holdings Inc. will present new data on florbetaben F 18 at the CTAD 2025 conference in San Diego. The study, to be presented by Marianne Chapleau, shows that florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab. The presentation will take place on December 3, 2025.
Lantheus Holdings Inc. announced that new data on florbetaben F 18 will be presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 conference, scheduled for December 1-4, 2025, in San Diego, CA. The poster presentation, titled “Florbetaben binding to amyloid plaques is unaffected by amyloid-targeting antibodies lecanemab and donanemab,” will be presented by Marianne Chapleau of Life Molecular Imaging on December 3, 2025. The study focuses on the use of florbetaben F 18, marketed as Neuraceq, for positron emission tomography (PET) imaging to estimate amyloid beta neuritic plaque density in adults with cognitive impairment. Results from this study will be presented at the upcoming conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9590876-en) on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
